The knockdown of NHP2 also suppressed HBx-transduced hepatoma cell growth in a xenograft animal model, suggesting that therapeutic approaches targeting NHP2 may provide a novel strategy for treating HBV-related HCC [142]. Here, NHP2 is linked to hepatocellular carcinoma.